From professional translators, enterprises, web pages and freely available translation repositories.
Add a translation
ranibizumab
lucentis
Last Update: 2011-08-02 Usage Frequency: 5 Quality: Reference: Wikipedia
prior ranibizumab
vorbehandelt mit ranibizumab
Last Update: 2017-04-26 Usage Frequency: 1 Quality: Reference: Wikipedia
group i ranibizumab
gruppe i ranibizumab 0,5 mg
ranibizumab 0.5 mg (n=130)
ranibizumab 0,5 mg (n=130)
Last Update: 2017-04-26 Usage Frequency: 2 Quality: Reference: Wikipedia
1 vial = 2.3 mg ranibizumab.
1 durchstechflasche = 2,3 mg ranibizumab.
Last Update: 2017-04-26 Usage Frequency: 3 Quality: Reference: Wikipedia
each ml contains 10 mg ranibizumab.
jeder ml enthält 10 mg ranibizumab.
one ml contains 10 mg of ranibizumab.
ein ml enthält 10 mg ranibizumab.
vial containing 2.3 mg of ranibizumab.
durchstechflasche enthält 2,3 mg ranibizumab.
Last Update: 2017-04-26 Usage Frequency: 4 Quality: Reference: Wikipedia
it contains the active substance ranibizumab.
sie enthält den wirkstoff ranibizumab.
Last Update: 2012-04-10 Usage Frequency: 3 Quality: Reference: Wikipedia
the active substance in lucentis is ranibizumab.
der wirkstoff von lucentis ist ranibizumab.
ham-controlled arm crossed-over to ranibizumab
scheininjektions-arm wechselte in ranibizumab-gruppe
it contains the active substance called ranibizumab.
die darin enthaltene aktive substanz wird ranibizumab genannt.
lucentis 10 mg/ml solution for injection ranibizumab
lucentis 10 mg/ml injektionslösung ranibizumab
the active substance is ranibizumab (10 mg/ml).
der wirkstoff ist ranibizumab (10 mg/ml).
for ranibizumab no clinical data on exposed pregnancies are available.
für ranibizumab liegen keine klinischen daten über exponierte schwangere vor.
lucentis 10 mg/ ml solution for injection ranibizumab intravitreal use
lucentis 10 mg/ml injektionslösung ranibizumab zur intravitrealen anwendung
each vial contains 2.3 mg of ranibizumab in 0.23 ml solution.
jede durchstechflasche enthält 2,3 mg ranibizumab in 0,23 ml lösung.
20 sham-controlled sham-controlled arm crossed-over to ranibizumab
durchschnittliche veränderung des visus vom ausgangswert +/- se (buchstaben)
crystal was a single-arm study with 0.5 mg ranibizumab monotherapy.
crystal war eine einarmige studie mit 0,5 mg ranibizumab als monotherapie.
this increased incidence was comparable between patients treated with ranibizumab and eylea.
diese erhöhte inzidenz war zwischen den patienten, die mit ranibizumab und eylea behandelt wurden, vergleichbar.